Oragenics Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Oragenics Inc. has filed its annual 10-K report detailing its 2023 financial performance and asset information.</b>

AI Summary

ORAGENICS INC (OGEN) filed a Annual Report (10-K) with the SEC on March 29, 2024. Oragenics Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. Key financial data points such as common stock, preferred stock, additional paid-in capital, and retained earnings for 2023 and 2022 are detailed. The report includes information on various assets including furniture and fixtures, laboratory equipment, leasehold improvements, and office/computer equipment as of December 31, 2023 and 2022. Details regarding Directors and Officers Liability insurance are provided for the period ending December 31, 2023.

Why It Matters

For investors and stakeholders tracking ORAGENICS INC, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Oragenics' financial position and operational details for the fiscal year 2023, which is crucial for investors to assess the company's performance and outlook. The detailed breakdown of assets and equity components allows stakeholders to understand the company's capital structure and resource allocation, aiding in investment decisions.

Risk Assessment

Risk Level: medium — ORAGENICS INC shows moderate risk based on this filing. The filing is a standard 10-K annual report, which typically contains a broad range of financial and operational information. Specific risk factors are not detailed in the provided header information, necessitating a review of the full document for a precise risk assessment.

Analyst Insight

Review the full 10-K filing to identify specific revenue figures, net income, EPS, debt-to-equity ratio, and any disclosed risk factors to form a complete investment thesis.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period end date)
• 2024-03-29 — Filing Date (Date the 10-K was filed)
• 2023-01-01 — Reporting Period Start (Start date of the fiscal year)
• 2023-12-31 — Reporting Period End (End date of the fiscal year)

Key Players & Entities

• ORAGENICS INC (company) — Filer name
• 1990 MAIN STREET (location) — Business address
• SARASOTA (location) — Business address city
• FL (location) — Business address state
• 34236 (location) — Business address zip
• 8132867900 (phone) — Business phone
• Odyssey Health Inc (company) — Mentioned in relation to Series F Preferred Stock

FAQ

Industry Context

Oragenics Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing products for infectious diseases and other therapeutic areas.

Regulatory Implications

As a publicly traded company, Oragenics Inc. is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the filing of annual 10-K reports.

What Investors Should Do

1. Analyze the full 10-K for detailed financial statements (income statement, balance sheet, cash flow).
2. Investigate any disclosed risk factors and management's discussion and analysis (MD&A).
3. Research any subsequent events or material changes reported in the filing.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-03-29: 10-K Filing Date — The date Oragenics Inc. officially submitted its annual report to the SEC.

Year-Over-Year Comparison

This is the initial analysis of the 2023 10-K filing. A comparison to the previous year's filing (2022) would require access to that document.

Key Financial Figures

• $0.001 — ange on which registered Common Stock $0.001 par value per share OGEN NYSE AMER
• $3.31 — mputed based upon a last sales price of $3.31 as reported by the NYSE American as of

Filing Documents

• form10-k.htm (10-K) — 2356KB
• ex4-8.htm (EX-4.8) — 71KB
• ex23-1.htm (EX-23.1) — 5KB
• ex23-2.htm (EX-23.2) — 4KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 12KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• ex97-1.htm (EX-97.1) — 36KB
• form10-k_001.jpg (GRAPHIC) — 9KB
• 0001493152-24-011979.txt (&nbsp;) — 6688KB
• ogen-20231231.xsd (EX-101.SCH) — 40KB
• ogen-20231231_cal.xml (EX-101.CAL) — 60KB
• ogen-20231231_def.xml (EX-101.DEF) — 129KB
• ogen-20231231_lab.xml (EX-101.LAB) — 375KB
• ogen-20231231_pre.xml (EX-101.PRE) — 295KB
• form10-k_htm.xml (XML) — 577KB

FORWARD-LOOKING STATEMENTS AND CERTAIN CONSIDERATIONS

FORWARD-LOOKING STATEMENTS AND CERTAIN CONSIDERATIONS i PART I ITEM 1.

BUSINESS

BUSINESS 1 ITEM 1A.

RISK FACTORS

RISK FACTORS 26 ITEM 1B. UNRESOLVED STAFF COMMENTS 69 ITEM 1C. CYBERSECURITY 69 ITEM 2.

PROPERTIES

PROPERTIES 69 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 69 ITEM 4. MINE SAFETY DISCLOSURES 69 PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 70 ITEM 6. RESERVED 70 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 70 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 83 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 83 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 83 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 83 ITEM 9B. OTHER INFORMATION 85 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 85 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 86 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 90 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS 104 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 105 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 106 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 107 ITEM 16. FORM 10-K SUMMARY 107

SIGNATURES

SIGNATURES 108 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM F-2 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM F-3 CONSOLIDATED BALANCE SHEETS F-4 CONSOLIDATED STATEMENTS OF OPERATIONS F-5 CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY F-6 CONSOLIDATED STATEMENTS OF CASH FLOWS F-7 CONSOLIDATED NOTES TO FINANCIAL STATEMENTS F-8 FORWARD LOOKING STATEMENTS AND CERTAIN CONSIDERATIONS This report, along with other documents that are publicly disseminated by us, contains or might contain forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements included in this report and in any subsequent filings made by us with the Securities and Exchange Commission (the "SEC") other than statements of historical fact, that address activities, events or developments that we or our management expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements represent our reasonable judgment on the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially. We claim the protection of the safe harbor for forward-looking statements provided in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Examples of forward-looking statements include: (i) projections of revenue, earnings, capital structure and other financial items, (ii) regarding us or our business. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as "believes," "expects," "estimates," "may," "will," "should," "could," "seeks,"

View Full Filing

View this 10-K filing on SEC EDGAR